SCHEMBL7263236

SCHEMBL7263236

O=C(O)Cc1ccncc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 14/20 0.48
KDM6B O15054 7/20 0.48
KDM4D Q6B0I6 4/20 0.48
KDM4E B2RXH2 3/20 0.48
MAPT P10636 2/20 0.48
KDM4A O75164 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NAPRT Q6XQN6 2/20 0.47
CYP1A2 P05177 1/20 0.44
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
AKR1B1 P15121 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
BCAT2 O15382 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370442 0.85 KDM4C (0.46) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL30465694 0.82 KDM4C (0.51) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL123203 0.82 KDM4C (0.51) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL3880004 0.82 KDM4C (0.50) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL28022089 0.82 NAPRT (0.46) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL2479238 0.81 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL3931892 0.81 KDM4C (0.48) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL6207070 0.81 KDM4C (0.48) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL7509912 0.81 KDM4C (0.48) KDM4CKDM6BKDM4DKDM4EMAPT
SCHEMBL9858541 0.79 KDM4C (0.47) KDM4CKDM6BKDM4DKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545013-B2 Of squaric acids; inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-04-08 US disclosed
EP-1286995-A1 2,7-NAPHTHYRIDINE DERIVATIVES Celltech R&D Limited (GB) 2003-03-05 EP disclosed
US-20020115684-A1 2, 7-naphthyridine derivatives CELLTECH R&D, LTD. (GB) 2002-08-22 US disclosed
WO-2001092256-A1 2,7-NAPHTHYRIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115684-A1 2, 7-naphthyridine derivatives VCAM1, ICAM1, SELL KDM4C 4656/4885KDM6B 4423/4885KDM4D 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.